US3707353A - Radioactive labeling kit - Google Patents

Radioactive labeling kit Download PDF

Info

Publication number
US3707353A
US3707353A US22765A US3707353DA US3707353A US 3707353 A US3707353 A US 3707353A US 22765 A US22765 A US 22765A US 3707353D A US3707353D A US 3707353DA US 3707353 A US3707353 A US 3707353A
Authority
US
United States
Prior art keywords
container
microparticles
labeling
compartment
vial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US22765A
Other languages
English (en)
Inventor
David O Kubiatowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of US3707353A publication Critical patent/US3707353A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S206/00—Special receptacle or package
    • Y10S206/828—Medicinal content
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S422/00—Chemical apparatus and process disinfecting, deodorizing, preserving, or sterilizing
    • Y10S422/903—Radioactive material apparatus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation

Definitions

  • a single-unit labeling kit for radioactively labeling biodegradable microparticles for medical diagnosis and the like comprises, generally, a container having at least one open end; a porous filter plate mounted within the container separating the container into first and second compartments; a plurality of biodegradable microparticles in the first compartment; a solid source of hydrogen ion in the second compartment; a reagent tablet in the first compartment, the tablet comprising a reducing reagent and a non-reactive, non-toxic wetting agent to aid in forming a Suspension of the microparticles when a liquid is introduced into the container; and means to temporarily seal the open end of the container, such means capable of receiving a syringe needle for placing a liquid in
  • the microparticles are labeled by introducing a solution containng radioactive technetium into the end of the container carrying the solid source of hydrogen ion, acidifying the solution by passing it through the solid source of hydrogen ion and through the porous filter plate into the first compartment, agitating the acidified solution to suspend the microparticles and dissolve the reagent tablet, heating the container to complete the labeling reaction, cooling the container, and removing the supernatant containing unreacted radioactive elements and spent reagents, leaving the labeled microparticles behind on the porous filter plate which may thereafter be removed for use.
  • the present invention relates to a labeling kit for radioactively labeling bodegradable microparticles for medical diagnosis. More particularly, the invention relates to a simplified system for labeling biodegradable microparticles by using a special reaction container containing therein all the necessary in'gredients for such labeling exclusive of the short half-life labeling radionuclide.
  • radioactvely labeled microparticles are used in hospitals and clinics as the desired radioactive emissions of these partcles are useful for diagnostic, prophylactic, and therapeutic purposes.
  • such tagged or labeled microparticles may be injected into the blood stream to be later filtered out by the lung.
  • a lung scanner may then be used to scan the body to obtain an Outline of the lung on an oscilloscope, paper, photograph, and the like. If such tagged partcles are not found in the lung, the physician may determine that there is not proper circulation in that lung.
  • a tumor is present in the body, such tumor, if vascular, would need a high concentration of blood.
  • the labeled microparticles in the blood would tend to concentrate at the tumor.
  • a radioactive nuclide commonly used to label partcles is radio-technetium (99mTc) obtainable from a commercial generator which is generally available in most hospital and clinics.
  • 99mTc radio-technetium
  • the components used to label the partcles are maintained separately outside the container in which the labeling is to be done. Dry microparticles are suspended in a detergent and Water, technetium is Patented Dec. 26, 1972 ICC added, sodium thiosulfate, a reducing reagent necessary for labeling with 99mTc, is added to the mixture, after which an acid is added to aid in the labeling, all of these ingredients being separately maintained outside the mixing vial. After the labeling reaction, not all of the radiotechnetium is attached to the partcles, leaving some in the solution.
  • the unbound technetium must be separated from the labeled microparticles. This is done by allowing the beads or partcles to settledown and thereafter decanting or V drawing off the waste reaction products and technetium. This is difiicult because some of the labeled partcles are also drawn off. Attempts have been made to label micropartcles in a filter vessel which obviates the need to decant or draw off waste reaction products and technetium. However, all of the components used to label the particles are maintained separately outside the filter vessel. Applicant is not aware at this time, of any convenient, single-unit radioactive labeling kit for labeling micropartcles.
  • a labeling kit system for conveniently labeling or *tagging biodegradable microparticles with a radioactive nuclide employs a special reaction container which contains all the necessary labeling ingredients therein exclusive of the nuclide.
  • the labeling kit comprises, generally, a container having at least one open end; a porous filter plate mounted with the container and separating the container into first and second compartments; a plurality of pharmaceutically acceptable microparticles in the lfirst compartment; at least one labeling reagent in said container; and means to temporarily seal the open end and capable of receiving a syringe needle for placing a liquid in the container and for the removal of radioactively labeled microparticles.
  • the components of the kit may vary depending upon the radio nuclides used to label the microparticles.
  • a non-reactive, non-toxic wetting agent may additionally be placed in the first compartment to aid in the suspension of the microparticles.
  • radio-technetium there is a reducing agent in the first compartment serving as the labeling reagent, and a solid source of hydrogen ion is in the second compartment.
  • labeling reagent is used herein to describe a material which causes either the microparticles or the radio nuclide used to label the microparticles, to assume a suitable state for attaching the radioactive nuclide to the microparticles.
  • one labeling reagent is Sodium thiosulfate which serves as a reducing agent, the purpose of which is to reduce the original pertechnetate to a usable lower oxidation form of technetium, the reduction being in the presence of acid.
  • both the reducing agent and a source of hydrogen ion are necessary ingredients in the labeling kit.
  • sodium paratoluene chloro-sulfonamide an oxidizing agent
  • a labeling reagent with radio-iodine is used as a labeling reagent with radio-iodine to oxidize the iodide to a usable labeling form which is done in the presence of suitable buffers, both the oxidizing agent and the butfers being components of the kit.
  • no labeling reagents are necessary when using radio-iron or radioindium, although, even here, a labeling reagent is preferred to insure the best results.
  • Such a labeling reagent would be ferric chloride in the presence of suitable bufers.
  • the actual mechanistic pathways involving the labeling reactions are uncertain at present. It is known, however, that certain labeling reagents are necessary when using certain radio nuclides, which are hereinafter described.
  • PIG. 1 is a partally cut-away view of the labeling kit of the present invention
  • FIG. 2 is an end view of the labeling kit along lines 2- 2 of FIG. 1, and
  • FIG. 3 is a sectional view, in perspective, taken along 3-3 of FIG. l.
  • the preferred labeling kit of the present invention comprises generally an elongated vial designed to have necksVV 17 and 27 on each end, each neck being open and capable of receiving stoppers 16 and 29 to seal the container.
  • a porous filter plate eg. sintered
  • the plate 22 is a glass frit and has deposited on the face 23 thereof, a pluralityw of biodegradable microparticles 19 which are to be labeled with a radionuclide and injected into the body for clinical diagnosis and the like.
  • the diameter of the vial is about mm. outer diameter in the center and about 17 mm. outer diameter in the neck.
  • the porous filter plate 22 has a diameter of about 13 mm.
  • the dimensions of the vial may vary depending on the use desired.
  • the porous filter plate 22, however, must be of a diameter' to completely fuse to the vial around the periphery of the plate.
  • the thickness of the plate is preferably about 21/2 mm. as such thickness is suitable for holding the microspheres and yet allowing saline solution introduced into the container during labeling to pass freely therethrough.
  • the pores of the porous filter plate are from about 5.5 to 6.5 microns.
  • the finely porous filter plate 22 may be made from suitable materials other than sintered glass, for example, porcelain, metal, plastic and the like.
  • the material used should be non-reactive with the ingredients in the vial and the pores should be such that they will prevent the microparticles from passing through.
  • a plurality of small acid resin particles 24 Immediately adjacent said plate 22 is depoSited a plurality of small acid resin particles 24.
  • the acid resin 24 is present to provide hydrogen ions which create an acid solution necessary to complete the labeling reaction.
  • the resin particles are held in place by means of a packing material 26 which in turn is held in place by a pharmaceutical rubber stopper 29.
  • a packing material 26 On the other end of the container (designated as B), the neck of the vial 14 is also stopped by means of the pharmaceutical rubber stopper 16, having an indentation 15 therein.
  • the purpose of the indentation 15 is to provide a space for the creation of reduced pressure in the vial during manufacture of the labeling kit. Other suitable means for creating such reduced pressure could be employed, thus eliminating the need of a stopper having a certain configuration.
  • the stoppers are sealed in the vial by means of aluminum caps 12 and which are crimped onto the vial.
  • a reagent tablet 20 Located in the central compartment 21 of the vial is a reagent tablet 20 containing, where necessary and desirable, a reducing reagent for the labeling reaction and a wetting agent to aid in suspending the microparticles.
  • sterile microparticles are suspended in an inert volatile solvent such as a mixture of diethylether and 1,1,2- trichloro-l,2,2-trifiuoroethane the latter ingredient availa'ble as Freon 113, the mixture preferably being 1/3 ether, 27s Freon.
  • an inert volatile solvent such as a mixture of diethylether and 1,1,2- trichloro-l,2,2-trifiuoroethane the latter ingredient availa'ble as Freon 113, the mixture preferably being 1/3 ether, 27s Freon.
  • the Suspension is aseptically dispensed into an empty sterile labeling vial with the end designated as B in an upward position.
  • the ether-Freon mixture is withdrawn by suction through end A at 28, allowing the microparticles, usually having a diameter of from about 15 to 30 microns, to be retained by the porous glass fn't or plate 22, the pores of which are smaller than'the diameter of the microparticles.
  • the sterile reag'ent tablet 20 is then added to the compartrnent through B and end B is temporarily closed with a rubber stopper 16.
  • the vial is then turned over with end A up and sterile acid resin particles 24 are added to the compartment through end A and are held in place' with packing material 26. End A is then stoppered and capped.
  • the vial is subjectedito reduced 'pressu're through end B to create a slight vacuum of about 1/5 atmosphere after which end B is also capped.
  • the microparticles do not have to be deposited on the plate 22 although this is preferred as the particles may conveniently be dispens'ed in'a known volume of solvent rather than having to be wei'ghed.
  • the microparticles could be merely placed loosely in the container or could be included in the reagent tablet.
  • the vial can be made longer, shorter, broader, or thinner varying the dimensions in a number of ways, it.being important only that the vial have at least one open end for receiving the appropriate lquds and for removing liquids and the labeled 'microparticles
  • the vial may be made from materials other than glass which are sterilizable, non-reactive, non-toxic and capable of withstanding relatively high temperatures, for example, polytetrafluoroethylene (Teflon). Glass is preferred because the labeling reaction may be visually observed, it is chemically inert, and because of its pharmaceutcal acceptability.
  • microparticles which may be used for purposes of the present inventionl are particular compositions comprising a physiologically acceptable, solid, substantially water-insoluble (at body temperature) material which can be metabolized or degraded in a manner which does not form toxic' residues when solubiliZed (apparently by enzymes or other metabolic mechanisms) in the parental body fiuids, such as blood, serum, plasma, lymph, and the like. When so metabolized or degraded, these substances are solubilized.
  • Suitable materials for the particular composition are physiologically acceptable proteinaceous substances, such as albumin, gelatin, hemoglobin, and the like, or polysaccharides such as amylose, inulin, glycogen, and starch or the same material containing a physiologically acceptable carrier such as ferric hydroxide, silver iodide, or the like.
  • physiologically acceptable carrier such as ferric hydroxide, silver iodide, or the like.
  • the material is prepared in a finely divided state, the sizes of the particles being closely controlled by sorting techniques so as to be in a narrow size range adapted to the specific use.
  • spheroidal or essentially'spherular particles are employed as they are more uniform and more easily Controlled with respect to radionuclide content and time of ⁇ elimination from the body.
  • Spherules from '1/2 to ⁇ 60 'microns in diameter are most useful for diagnostic purposes. Larger Spherules, even up to 1 mm. in diameter, can be used for-certain therapeutic purposes.
  • spheroidal or spherular particles are more easily Controlled with respect to radionuclide content and time of elimination from the body. Particularly, they are preferred because, by matchin'g the diameter of the spheroid to the size of the body passa'ges, eg.
  • the total weight of the microspheres preferably used in the labeli'ng vial of the present invention can vary from about 0.1'to 50 mg. while the size of individual microspheres can vary from about 1/2 to microns'
  • the solid source of hydrogen ion is used to acidify the radioactive nuclide solution that passes through the porous filter plate into the container carrying the tablet when radio-technetium is used. The acidification is required to aid in the labeling reaction although the exact mechanisrn is not known.
  • a useful solid acid material is a strongly acidic cation exchange resin composed of nuclear sulfonic acid exchange groups attached to a styrene divinylbenzene polymer lattice, available commercially under the trade name Dowex 50X8. Similar types of resins which may be used are Duolite C-20, Amberlite IR-l20, Zeocarb 225, Nalcite HCR, and S-ll Other types of strong acid resins may also be used.
  • a resin containing methylene sulfonic groups on a phenolic lattice is represented by the following trade names: Bio-'Rex-40, Duolite C-3ab, and Zeocarb-ZlS.”
  • Crystalline acids VsuchV as trichloroacetic acid, citric acid, potassium bisulfate and others can be used in place of the acid resin.
  • the solid source of hydrogen ion makes available a mobile hydrogen ion which may be exchanged with a sodium ion from the saline solution containing the radionuclide which is introduced into the container.
  • Sodium ions react with the resin to release a chemically equivalent amount of hydrogen ions.
  • the amount of hydrogen ions released, acidifying the radionuclide-carrying saline solution is controlled by the amount of the resin that is used.
  • the configuration of the acid resin is preferably spherular to present a relatively uniform surface area for ion exchange to achieve uniform flow rate, for ease of dispensing, and its use results in freedom from small particles.
  • the diameter of the spherules is from about 50-1000 microns, and preferably 500-700 microns.
  • the packing material 26 can be glass wool, cotton, plastic, Sponge or other porous materials, or the packing may be eliminated altogether.
  • the packing is helpful to insure that none of the resin will escape the vial during manufacture and also to disperse the resin over a fairly uniform surface area. It is further helpful in insuring that there is a space between the stopper 29 and the resin 24 for the insertion of the solution containing the radionuclide.
  • the reagent tablet 20 basically comprises sodium thiosulfate, where radio-technetium is used, and a wetting agent such as detergent.
  • the sodium thiosulfate aids in the labeling reaction as a reducing reagent while the wetting agent aids in the suspension of the microspheres to insure uniform labeling
  • the reducing agent aids in the reduction of 99mTcOf, the state in which technetium is generally obtained, when in the presence of acid.
  • the remaining ingredients in the tablet are generally inert and may be any of several pharmaceutical adjuvants which are generally used in the manufacture of tablets, such as a filler (lactose), binder (polyvinylpyrrolidone) and a lubricant (benzoic acid).
  • the dimensions and composition of the reagent tablet can be varied or the tablet can be eliminated and replaced with sodium thiosulfate crystals or a mixture of sodium thiosulfate and an inert filler such as lactose.
  • the sodium thiosulfate content of the reagent tablet may vary from 0.5 mg. to 10 mg.
  • Other known reagents may be used in place of the sodium thiosulfate such as thioacetamide, tin, zinc, stannous chloride, although the sodium thiosulfate is preferred because of its performance in the labeling reaction.
  • radionuclides other than radio-technetium are used, other suitable reagents are used where necessary.
  • an oxidizing agent sodium para-toluene chloro-sulfonamide, available as Chloramine T, is used with radio-iodine, and, buifer salts such as sodium dihydrogen phosphate and disodium hydrogen phosphate, in combination with ferric chloride, are used with radio-iron and radio-indium.
  • buifer salts such as sodium dihydrogen phosphate and disodium hydrogen phosphate, in combination with ferric chloride
  • the use of a reagent is optional although generally preferred for most applications.
  • labeling may be accomplished by agitating the microparticles 'in a solution containing the radioactive nuclide, thus not using a wetting agent, solid acid materials, or reducing agents as components of the kit.
  • the reagent or reagents may be in either the first or second compartment or both.
  • the labeling reagent, sodium thiosulfate is in the first compartment designated at 21 whilte the solid source of hydrogen ion or acid resin 24 is in the second compartment so that the solution is acidified when it comes in contact with the reagent.
  • sodium paratoluene chloro-sulfonamide is used as the labeling reagent, it may be in either compartment, preferably the first, while the buffer may also be in either compartment, but preferably the second. What is unique is that all of the reagents, whatever they are, are all contained within a single unit.
  • the radionuclide which is to be used to label the microspheres is obtained from a commercial generator generally referred to in the art as a cow.
  • exemplary of radioactive materials which may be used for labeling microparticles are radio-iodine, radio-iron, radio-technetium, radio-indium, and other suitable radionuclides, used in conjunction with suitable reagents.
  • Radio-technetium (99mTc) is preferably used because of its gamma emission energy and general availability.
  • Technetium is eluted from the generator, or c0w, by passing saline solution therethrough which carries the 99mTc out of the generator and into a collecting vial. The saline solution containing the radio-technetium is then Withdrawn from the vial by means of a syringe.
  • the needle of the syringe containing the radio-technetium in the saline solution is pushed through the rubber stopper 29 into end A of the vial at 28.
  • the reduced pressure inside the vial which was created during the manufacture thereof, draws the radio-technetium solution over the resin, through the glass frit and into compartment 21 at a controlled rate.
  • the ion exchange between the resin and the isotope-containing saline solution is as follows:
  • the flow rate is important because as the radiotechnetium passes over the resin, the sodium ions in the saline solution exchange with the hydrogen ions in the resin. If the solution passes too rapidly over the resin, there will not be a proper exchange of sodium and hydrogen ions. Thus, this rate must be controlled.
  • the vial, containing the radio-technetium in solution in the compartment containing the tablet may be immersed in an ultrasonic bath to aid in suspending the microspheres deposited on the glass frit and to help dissolve the tablet. As the tablet is dissolved, sodium thiosulfate and the detergent are released. The vial is then immersed in Warm,
  • the vial may then be cooled after which the supernatant containing the unreacted radio-technetium and spent reagents is withdrawn through the vial at end A, leaving the labeled microspheres behind on the porous filter plate 22 on the face 23 thereof.
  • Saline solution or other solutions used as a vehicle for injections
  • detergent can be added to compartment 21 through end B for Suspension and injection of the labeled microspheres, or the microspheres may be washed once or several times prior to injection with saline which is removed after washing as heretofore described.
  • microspheres smaller than 6 microns are to be labeled, such as those that might ibe used for liver scanning, the above procedure is followed except that the supernate is not withdrawn through end A. Rather, a suitable buffer, such as Sodium dihydrogen phosphate and disodium hydrogen phosphate, in combination, is added to compartment 21 through end B to neutralize the acid of the reaction. The small microspheres are then injected in this buffered solution.
  • a suitable buffer such as Sodium dihydrogen phosphate and disodium hydrogen phosphate, in combination
  • the kit can be made to contain its own 99mTc generator such that the user would not need a commercial generator on hand. Such a complete kit would be useful to the investigator whose clinical volume is not large enough to justify the purchase of a separate 99mTc generator.
  • about 100 mg. of granular aluminum oxide is sandwiched between the resin 24 and the packing 26.
  • About to 100 millicuries, preferably about 20 millicuries of (NHUZBQMoOt-QHITCO., (ammonium molybdate) is pipetted onto the top of the aluminum oxide and dried. The amount of arnmonium molybdate used must be sufficient to produce an effective labeling amount of radiotechnetium.
  • End A is then sealed after which the vial is evacuated through end B and sealed.
  • a needle of a syringe containing about ml. saline solution is pushed through the rubber stopper 29 at A, the inside vacuum of the vial (Ms atmosphere) draws the saline over the aluminum oxide, over the resin 24, through the porous filter plate 22 and into the center compartment 21 at a Controlled rate.
  • Nam TcO. is stripped from the absorbed (NHzgiiMoO which remains immobile.
  • HCI is obtained such that acidified Na99mTcO4L passes through the porous filter plate 22 into compartment 21. 'Ihe kit is then used as heretofore described.
  • labeled colloidal sulfur also sometimes referred to as sulfur colloid
  • the labeled colloidal sulfur may be prepared using the labeling kit of the present invention simply by leaving out the microparticles. The same procedure is followed as with labeling micropsheres except that the supernate is not removed but a buifer solution is added to neutralize the acid of reaction and the 9gmTc colloidal sulfur is ready for use.
  • the use of human serum albumin microparticles is preferred, however, because of their constancy of Size and physical stability characteristics.
  • Example 1 Four milliliters of a commercially-obtained pharmaceutical grade of human serum albumin (obtained from E. R. Squibb & Sons, New York, N.Y.) were injected, conveniently through a hypodermic needle, in about 1 liter of vegetable oil (cotton seed oil) which was heated to about 30-50 C. The rate of stirring determines the ultimate size of the spherule material obtained. Using a container which was greater in height than in diameter, with a 25 gauge hypodermic needle and stirring at about 500 r.p.m. with a 21/2 inch propeller-type stirrer microspherular particles of about 10-20 microns in diameter were obtained. Stirring was continued while heating to 110-150 C.
  • human serum albumin obtained from E. R. Squibb & Sons, New York, N.Y.
  • Example 2 A radioactive labeling kit according to the present invention was prepared as follows: Sterile human serum albumin microspheres were suspended in 200 ml. of a mixture of diethylether and 1,1,2-trichloro-1,2,2-trifiuoroetha'ne (1/3 ether and 2/3 of 1,1,2-trichloro-1,2,2-tritluoroethane). To obtain about 5 mg. of microspheres, 1 ml. of the mixture was withdrawn and aseptically dispensed into an empty Sterile labeling vial as illustrated in the drawings with end B in an upward position. The ether and 1,1,2-trichloro-1,2,2-trifluoroethane mixture was Withdrawn by suction through the opposite end A.
  • the microspheres of 15-30 microns in diameter were retained by the porons glass frit having pores of 5.5-6.5 microns.
  • a Sterile reagent tablet was added to the vial through end B which then was temporarily closed with a rubber stopper.
  • the reagent tablet was of the following composition:
  • Lactose 67.2 Non-ionic surfactant of poly(oxethylene), poly(oxpropylene)7 and poly(oxethylene) polymer (Pluronic 17-68) 0.3 Polyvinylpyrrolidone 1.66 Benzoic acid 6.0
  • Example 3 The labeling vial prepared according to Example 2 was used to label human serum albumin microspheres with radio-technetium (Na99mTcO4).
  • the needle of a syringe containing 6 ml. (about 12 millicuries) of Na99mTcO4 in saline solution obtained from a commercial generator was inserted into the resin-containing end of the glass vial.
  • the inside vacuum of the vial (about 1/3 atmosphere) pulled the Na99mTcO4 solution over the Dowex resin, through the glass frit and into the center of the vial where the reagent tablet Was located.
  • the vial was then agitated and sonicated in an ultrasonic bath for 2 min. to dissolve the tablet and release Sodium thiosulfate and the detergent.
  • the vial was removed from the bath and placed in boiling water and agitated for 6 min. to complete the labeling reaction after which the vial was cooled in tap water for 2 min.
  • the supernate containing unreacted Na99m'l ⁇ c04 and spent reagents was then withdrawn with a syringe through the end of the vial designated as A in the drawings and containing the resin and packing.
  • the labeled microspheres remained behind deposited on the glass frit.
  • Six ml. of isotonic saline solution containing 0.05% Polysorbate was added to the vial through the other end of the vial designated as B to resuspend the labeled microspheres.
  • the labeled microspheres were then tested in mice by withdrawing 0.2 ml. of the saline solution With Polysorbate 80 and containing 0.1 mg. of 99mTc labeled microspheres (about 0.2 millicuries) and injecting the mixture TABLE I Standard deviation Average (each kit) Percent uptake 79. 5. 7 Percent in lung.. 77.0 5. 7 Percent in liver 5. 8 1. 2 Percent in carcas 12. 2 4. 8 Lung/liver ratio-" 14. 1 4. 6
  • Example 4 Animal testing similar to that of Example 3 was performed using a vial as prepared in Example 2 except that 350 mg. of Dowex resin and ml. of NaWmTcO4 ⁇ (about 20 millicuries) were used.
  • the reagent tablet had the following composition:
  • Lactose V 65.20 Non-ionic surfactant of poly(oxethylene), poly- (oxpropylene) and poly(oxethylene) polymer (Pluronic 17-68) 1.00
  • the labeled microspheres were washed with 10 ml. of saline solution (containing 0.05% Polysorbate 80, a mixture of polyoxethylene ethers of mixed partial oleic esters of sorbitol anhydrides) which was placed into the vial at B and withdrawn through end A.
  • saline solution containing 0.05% Polysorbate 80, a mixture of polyoxethylene ethers of mixed partial oleic esters of sorbitol anhydrides
  • a container having at least one open end
  • a porous filter plate mounted within said container and separating said container into first and second compartments;
  • labeling kit of claim 1 wherein the labeling reagent is a reducing agent and in said first compartment.
  • the labeling kit of claim 2 additionally having a solid source of hydrogen ion in said second compartment.
  • said solid source 10 of hydrogen ion is a strongly acidic cation exchange resin composcd of nuclear sulfonic acid exchange groups attached to a styrene divinylbenzene polymer lattice.
  • the labeling kit of claim 3 additionally having a packng material in said second compartment for preventing movement of said solid source of hydrogen ion.
  • a glass frit mounted transversely within said container and separating said container into first and second compartments;
  • a reagent tablet in said first compartment said tablet comprising a reducing agent to aid in the labeling reaction and a non-reactive, non-toxic, wetting agent to aid in the Suspension of said microspheres when a liquid in said container is introduced into said container;
  • the labeling kit of claim 7 additionally having a packng material in said second compartment for preventing movement of said solid source of hydrogen ion.
  • said wetting agent is a non-ionic surfactant of poly(oxethylene), poly- (oxpropylene), and poly(oxethylene) polymer.
  • said solid source of hydrogen ion is a strongly acidic cation exchange resin composcd of nuclear sulfonic acid exchange groups attached to a styrene divinylbenzene polymer lattice.
  • a single-unit labeling kit for providng a radionuclide and thereafter labeling pharmaceutically acceptable microparticles with said radionuclde by means of a labeling reaction comprising:
  • a container having at least one open end
  • a porous filter plate mounted transversely within said container and separating said container into first and second compartments;
  • a reagent tablet in said co'mpartment said tablet comfprising a reducing reagent to aid in the labeling reaction and a non-reactive, non-toxic wetting agent to aid in the Suspension of said microparticles when a liquid is introduced into said container;
  • the labeling kit of claim 12 additonally having packng in said second compartrnent to hold said aluminum oxide layer against said resin and firmly in said container.
  • microparticles are biodegradable microspheres.
  • said solid source of hydrogen ion is a strongly acidic cation exchange resin composed of nuclear sulfonic acid exchange groups attached to a styrene divinylbenzene polymer lattce and said tablet comprises sodium thiosulfate, a nonionic surfactant of poly(oxethylene), poly(oxpropy1ene), and poly(oxethylene) polymer, and pharmaceutically acceptable adjuvants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US22765A 1970-03-26 1970-03-26 Radioactive labeling kit Expired - Lifetime US3707353A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2276570A 1970-03-26 1970-03-26

Publications (1)

Publication Number Publication Date
US3707353A true US3707353A (en) 1972-12-26

Family

ID=21811314

Family Applications (1)

Application Number Title Priority Date Filing Date
US22765A Expired - Lifetime US3707353A (en) 1970-03-26 1970-03-26 Radioactive labeling kit

Country Status (9)

Country Link
US (1) US3707353A (enrdf_load_stackoverflow)
JP (1) JPS5127158B1 (enrdf_load_stackoverflow)
BE (1) BE764814A (enrdf_load_stackoverflow)
CA (1) CA948103A (enrdf_load_stackoverflow)
CH (1) CH572734A5 (enrdf_load_stackoverflow)
DE (1) DE2115066A1 (enrdf_load_stackoverflow)
FR (1) FR2087863A5 (enrdf_load_stackoverflow)
GB (1) GB1343154A (enrdf_load_stackoverflow)
IT (1) IT972075B (enrdf_load_stackoverflow)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3918909A (en) * 1971-09-21 1975-11-11 Philips Corp Apparatus for performing saturation analyses
US3926176A (en) * 1973-08-15 1975-12-16 Gen Electric Radioactive gas-containing polymeric capsule
US4031198A (en) * 1972-08-30 1977-06-21 Minnesota Mining And Manufacturing Company Technetium-labeled complexes, production and use thereof
US4162142A (en) * 1978-06-29 1979-07-24 The United States Of America As Represented By The United States Department Of Energy Tritium labeling of organic compounds deposited on porous structures
US4765655A (en) * 1986-04-22 1988-08-23 Crihan Ioan G Radioisotope marking of art objects in view of their rapid identification
WO2007092981A1 (de) * 2006-02-14 2007-08-23 Medizinische Universitaet Wien Synthesebehälter, synthesevorrichtung und syntheseverfahren zur herstellung einer pharmazeutisch aktiven substanz aus einer geeigneten vorläufersubstanz
WO2013049783A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Partitioned reaction vessels
US20140174978A1 (en) * 2011-07-12 2014-06-26 Algeta Asa Liquid container

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8310038D0 (en) * 1983-04-13 1983-05-18 Amersham Int Plc Technetium-99 labelled tin colloid

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3918909A (en) * 1971-09-21 1975-11-11 Philips Corp Apparatus for performing saturation analyses
US4031198A (en) * 1972-08-30 1977-06-21 Minnesota Mining And Manufacturing Company Technetium-labeled complexes, production and use thereof
US3926176A (en) * 1973-08-15 1975-12-16 Gen Electric Radioactive gas-containing polymeric capsule
US4162142A (en) * 1978-06-29 1979-07-24 The United States Of America As Represented By The United States Department Of Energy Tritium labeling of organic compounds deposited on porous structures
US4765655A (en) * 1986-04-22 1988-08-23 Crihan Ioan G Radioisotope marking of art objects in view of their rapid identification
WO2007092981A1 (de) * 2006-02-14 2007-08-23 Medizinische Universitaet Wien Synthesebehälter, synthesevorrichtung und syntheseverfahren zur herstellung einer pharmazeutisch aktiven substanz aus einer geeigneten vorläufersubstanz
US20140174978A1 (en) * 2011-07-12 2014-06-26 Algeta Asa Liquid container
US9173814B2 (en) * 2011-07-12 2015-11-03 Algeta Asa Liquid container
WO2013049783A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Partitioned reaction vessels
CN103946925A (zh) * 2011-09-30 2014-07-23 通用电气健康护理有限公司 分区的反应容器
AU2012315579B2 (en) * 2011-09-30 2015-06-18 Ge Healthcare Limited Partitioned reaction vessels
EP2761623A4 (en) * 2011-09-30 2016-01-20 Ge Healthcare Ltd PARTITIONED REACTION VESSELS

Also Published As

Publication number Publication date
BE764814A (fr) 1971-09-27
IT972075B (it) 1974-05-20
JPS5127158B1 (enrdf_load_stackoverflow) 1976-08-11
CH572734A5 (enrdf_load_stackoverflow) 1976-02-27
CA948103A (en) 1974-05-28
FR2087863A5 (enrdf_load_stackoverflow) 1971-12-31
DE2115066A1 (de) 1971-10-07
GB1343154A (en) 1974-01-10

Similar Documents

Publication Publication Date Title
Zolle et al. Preparation of metabolizable radioactive human serum albumin microspheres for studies of the circulation
Holman et al. A new Tc-99m-labeled myocardial imaging agent, hexakis (t-butylisonitrile)-technetium (I)[Tc-99m TBI]: initial experience in the human
US12249437B2 (en) Production of highly purified 212PB
US3707353A (en) Radioactive labeling kit
JPS58146514A (ja) テクネチウム−９９ｍで標識付けされるべき対象探査性配位子および非一対象探査性還元体を有する容器
Yeong et al. Neutron-activated 153Sm-ion-exchange resin as a tracer for gastrointestinal scintigraphy
Yvert et al. Simple, fast preparation of gallium-68-labelled human serum albumin microspheres
Briner Preparation of 125I-labeled micro-aggregated human serum albumin for use in studies of reticuloendothelial function in man
Mock et al. Stoichiometric Tc-99m RBC labeling using stable kit solutions of stannous chloride and EDTA: concise communication
O'Brien et al. Preparation of 99mTc-Nanocoll for use in sentinel node localization: validation of a protocol for supplying in unit-dose syringes
Honda et al. Instant labeling of macro-and microaggregated albumin with 99mTc
Mushtaq et al. Adsorption of 99mTc-radiopharmaceuticals onto injection vials and syringes
US4789541A (en) Method and composition for in vivo radiolabeling of red blood cells with 99m Tc
Zalutsky Radioactive noble gases for medical applications
US12406776B2 (en) Production of highly purified 212Pb
Hojelse et al. Factors which affect the integrity of radiopharmaceuticals
Shukri The extraction of iodine-131 from the spillage using coconut shell activated carbon in nuclear medicine.
TW448296B (en) The novel preparation of Re-188 sulfur colloid
Hupp et al. Unit dose radiochemical stability of commonly used technetium-99m radiopharmaceuticals
Staum Landmarks and landmines in the early history of radiopharmaceuticals
Mani Radiopharmacy practices
Stoffer et al. Usefulness of liquid radioiodine in avoiding factitious low I-131 uptake studies
Rothchild Radioactive drugs in clinical medicine
DE2166643A1 (de) Verfahren zum radioaktiven kennzeichnen von pharmazeutisch unbedenklichen mikropartikeln
Vyth et al. Labelling of red blood cells with 99m pertechnetate